Clinical trials: Malignant Tumor With Metastasis
Secondary Malignant Neoplasm of Spine
Single Versus Multiple Fractionated SSRS for Spinal Metastases
The investigators proposed this randomized study to determine the feasibility of delivering single-fraction 16-Gy versus 3-fraction 24-Gy toward spine metastatic lesion and to evaluate their toxicity profiles.
- Trial name
- NCT02608866
- Testing
- SF-SSRS, MF-SSRS
- Where
- Taiwan
- Volunteers
- 68 people
- Sponsor
- National Taiwan University Hospital
Fatigue Related to Cancer Treatment, Colon Cancer
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.
The goal of this clinical trial is to evaluate whether Nuvastatic 300 capsule can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy.
- Trial name
- NuvastaticTM (NCT07669454)
- Testing
- Nuvastatic 300
- Where
- 6 sites in India
- Volunteers
- 250 people
- Sponsor
- Natureceuticals Sdn Bhd
Solid Tumor, Adult, Locally Advanced Solid Tumor
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib
Larotrectinib, a selective TRK inhibitor has showed marked and durable antitumor activity in patients with NTRK gene-fusion-positive tumors regardless of the tumor type, gene partner and patient's age.
- Conditions
- Solid Tumor, Adult, Locally Advanced Solid Tumor, Metastatic Cancer
- Trial name
- LAROTRACKING (NCT04814667)
- Where
- 4 sites in France
- Volunteers
- 26 people
- Sponsor
- Centre Leon Berard
Metastatic Cancer
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
This is a Phase I/II study to investigate the feasibility of creating a personalized therapeutic cancer vaccine within the body. A vaccine contains a source of tumor antigen and an adjuvant.
- Trial name
- NCT00861107
- Testing
- AlloStim-7, percutaneous tumor cryoablation, AlloStim8 or AlloStim-9
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mirror Biologics, Inc.
Biliary Tract Cancer, Colorectal Carcinoma
CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
The investigational product used in this study, UCLH801 cells, is a CAR-T cell therapy specifically targeting CDH17. The proposed indication includes CDH17-positive advanced solid tumors, such as but not limited to colorectal…
- Conditions
- Biliary Tract Cancer, Colorectal Carcinoma, Gastric Cancer, Metastatic, Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
- Trial name
- NCT06937567
- Testing
- CDH17 CAR-T, FAST LACO-Stim CDH17 CAR-T
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhejiang University
Non-small Cell Lung Cancer, Esophageal Cancer
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery.
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT02838836
- Testing
- Study sample collection
- Where
- United States
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
This phase I/II trial studies the side effects and best dose of avelumab with M6620 in treating patients with deoxyribonucleic acid (DNA) damage repair (DDR) deficient solid tumors that have spread to other places in the body…
- Conditions
- Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04266912
- Testing
- Avelumab, Berzosertib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor that has spread to other places in the body (metastatic), does not respond to treatment (refractory), or cannot be…
- Conditions
- Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Refractory Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02893930
- Testing
- Sapanisertib
- Where
- 405 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors, Colorectal Cancer
L19TNFα in Patients With Advanced Solid Tumors
The recombinant human fusion protein L19TNFα was created with the intention to overcome the systemic toxicity of TNFα by directly targeting it to tumor tissues.
- Trial name
- NCT01253837
- Testing
- L19TNFa
- Where
- 2 sites in Italy
- Volunteers
- 34 people
- Sponsor
- Philogen S.p.A.
Sarcoma
Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276692
- Testing
- irinotecan hydrochloride
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 35 people
- Sponsor
- Children's Cancer and Leukaemia Group
Kidney Cancer
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's lymphocytes to kill kidney cancer cells.
- Trial name
- NCT00085436
- Testing
- Aldesleukin,, autologous tumor cell vaccine, recombinant interferon alfa
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Solid Tumor
Study of ORIC-101 in Combination With Anticancer Therapy
The purpose of this study is to establish the recommended Phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with nab-paclitaxel or other…
- Trial name
- NCT03928314
- Testing
- ORIC-101, Nab-paclitaxel
- Where
- 12 sites in United States
- Volunteers
- 83 people
- Sponsor
- ORIC Pharmaceuticals
Prostate Cancer
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
Oligo-metastatic prostate cancer (OMPCa) is considered as an intermediated state between localized and poly-metastatic disease. Various retrospective studies and prospective clinical trials are carrying out to validate whether…
- Trial name
- NCT05212857
- Testing
- Leuprolide acetate, Goserelin acetate, Triptorelin acetate
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
This early phase I trial tests the use of a radioactive tracer (a drug that is visible during an imaging test) known as 18F-FMAU, for imaging with positron emission tomography/computed tomography (PET/CT) in patients with brain…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Glioma, Malignant Brain Neoplasm
- Trial name
- NCT04752267
- Testing
- Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Solid Tumor
Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in China
The primary objective is to evaluate the safety and, tolerabilitytolerance, pharmacokinetices and immunogenicity of escalating single doses and subsequent multiple dose of Gentuximab Injection in patients with late recurrence of…
- Trial name
- NCT03313219
- Testing
- Gentuximab Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
The purpose of the phase 2 component of this study is to determine if giving the immune molecule NPC-1C to individuals who have cancer of the pancreas or gastrointestinal tract (colon or rectum) which has not responded to…
- Trial name
- NCT01040000
- Testing
- NPC-1C/NEO-102
- Where
- 6 sites in United States
- Volunteers
- 94 people
- Sponsor
- Precision Biologics, Inc
Advanced Solid Tumor, Metastatic Solid Tumor
Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Immunotherapy Alone or in Combination With Chemotherapy
ACM-CpG is a CpG-B TLR9 agonist, which in animal models has led to shrinkage and complete disappearance of injected tumors, durable antitumor memory, and growth inhibitory effects on non-injected tumors while intramuscular…
- Trial name
- NCT06587295
- Testing
- Intramuscular ACM-CpG Monotherapy (Escalation), Intramuscular ACM-CpG Monotherapy (Expansion)
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- National Cancer Centre, Singapore
Pancreatic Tumor, Periampullary Carcinoma Resectable
Role of CTC´s Spread During Pancreaticoduodenectomy in Patients With Pancreatic and Periampullary Tumors
This multicentre, prospective and randomized study aims(1:1) to compare the rate of recurrence, metastasis and survival according to the levels of intraoperative circulating tumor cells (CTCs) during cephalic…
- Conditions
- Pancreatic Tumor, Periampullary Carcinoma Resectable, Circulating Tumor Cells, Metastasis
- Trial name
- CETUPANC (NCT03340844)
- Testing
- No Touch (NT), Superior Mesenteric Artery First (SMA)
- Where
- Spain
- Volunteers
- 86 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Pain; Bone Neoplasms; Neoplasm Metastasis
A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.
This single arm study will assess the efficacy and safety of loading doses of intravenous Bondronat in patients with breast cancer and malignant bone disease experiencing moderate to severe bone pain.
- Trial name
- NCT00502736
- Testing
- ibandronate [Bondronat]
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 13 people
- Sponsor
- Hoffmann-La Roche
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either…
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00950911
- Testing
- amg 162
- Where
- 17 sites in Czechia, United Kingdom
- Volunteers
- 35 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.